Lexicon Pharmaceuticals, Inc.

As of October 31, 2025, Lexicon Pharmaceuticals, Inc. shows a bullish technical trend with strong moving averages and Bollinger Bands, despite mixed signals from KST and OBV indicators, and has significantly outperformed the S&P 500 year-to-date.

As of October 31, 2025, Lexicon Pharmaceuticals, Inc. shows a bullish trend supported by positive daily moving averages and monthly Bollinger Bands, despite mixed signals from KST and OBV indicators.

As of October 31, 2025, Lexicon Pharmaceuticals shows a bullish technical trend with strong year-to-date performance of 86.87%, despite mixed signals from some indicators and a longer-term underperformance of -29.23% over the past year.

As of October 15, 2023, Lexicon Pharmaceuticals, Inc. is considered attractive and undervalued with a P/E ratio of 12.5, a P/B ratio of 1.8, and a D/E ratio of 0.3, indicating a solid financial position compared to peers like Amgen and Gilead, and its stock performance has outpaced the Sensex.

As of October 1, 2023, there is not enough technical data for Lexicon Pharmaceuticals, Inc. to determine if it is bullish or bearish.

As of March 2022, the management team of Lexicon Pharmaceuticals, Inc. includes Mr. Lonnel Coats (CEO), Mr. Raymond Debbane (Chairman), and several independent directors: Mr. Philippe Amouyal, Dr. Samuel Barker, Dr. Robert Lefkowitz, Dr. Alan Nies, and Mr. Frank Palantoni. They oversee the company's strategic direction and operations.

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing treatments for human diseases, with a market cap of approximately $262.81 million. As of March 2025, it reported net sales of $1 million and a net loss of $25 million.